These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27711069)

  • 1. Rifaximin, Microbiota Biology, and Hepatic Encephalopathy.
    Peleman C; Camilleri M
    Clin Transl Gastroenterol; 2016 Oct; 7(10):e195. PubMed ID: 27711069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota.
    Wang MW; Ma WJ; Wang Y; Ma XH; Xue YF; Guan J; Chen X
    Front Microbiol; 2023; 14():1091167. PubMed ID: 37032856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition.
    Kang DJ; Kakiyama G; Betrapally NS; Herzog J; Nittono H; Hylemon PB; Zhou H; Carroll I; Yang J; Gillevet PM; Jiao C; Takei H; Pandak WM; Iida T; Heuman DM; Fan S; Fiehn O; Kurosawa T; Sikaroodi M; Sartor RB; Bajaj JS
    Clin Transl Gastroenterol; 2016 Aug; 7(8):e187. PubMed ID: 27560928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients.
    Zuo Z; Fan H; Tang XD; Chen YM; Xun LT; Li Y; Song ZJ; Zhai HQ
    Exp Ther Med; 2017 Nov; 14(5):4887-4895. PubMed ID: 29201193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
    Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
    Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
    Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
    World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of intestinal microbiota and serum metabolites in patients with mild hepatic encephalopathy.
    Lin Y; Yan G; Feng F; Wang M; Long F
    Open Life Sci; 2022; 17(1):139-154. PubMed ID: 35350446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.
    Gupta A; Dhiman RK; Kumari S; Rana S; Agarwal R; Duseja A; Chawla Y
    J Hepatol; 2010 Nov; 53(5):849-55. PubMed ID: 20675008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Minimal hepatic encephalopathy].
    Jover M; Hoyas E; Grande L; Romero-Gómez M
    Rev Gastroenterol Mex; 2009; 74(1):26-34. PubMed ID: 19666316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy.
    Romero-Gómez M; Ramos-Guerrero R; Grande L; de Terán LC; Corpas R; Camacho I; Bautista JD
    J Hepatol; 2004 Jul; 41(1):49-54. PubMed ID: 15246207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal hepatic encephalopathy: A review.
    Nardone R; Taylor AC; Höller Y; Brigo F; Lochner P; Trinka E
    Neurosci Res; 2016 Oct; 111():1-12. PubMed ID: 27153746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin Prevents T-Lymphocytes and Macrophages Infiltration in Cerebellum and Restores Motor Incoordination in Rats with Mild Liver Damage.
    Balzano T; Leone P; Ivaylova G; Castro MC; Reyes L; Ramón C; Malaguarnera M; Llansola M; Felipo V
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of Low-Grade Cerebral Edema After Lactulose/Rifaximin Therapy in Patients with Cirrhosis and Minimal Hepatic Encephalopathy.
    Rai R; Ahuja CK; Agrawal S; Kalra N; Duseja A; Khandelwal N; Chawla Y; Dhiman RK
    Clin Transl Gastroenterol; 2015 Sep; 6(9):e111. PubMed ID: 26378384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin for the treatment of hepatic encephalopathy.
    Mantry PS; Munsaf S
    Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of rifaximin in gastrointestinal and liver diseases.
    Shayto RH; Abou Mrad R; Sharara AI
    World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing.
    Zhang Z; Zhai H; Geng J; Yu R; Ren H; Fan H; Shi P
    Am J Gastroenterol; 2013 Oct; 108(10):1601-11. PubMed ID: 23877352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
    Brandl K; Schnabl B
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1069-76. PubMed ID: 26088524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.